Smoldering multiple myeloma

1 paper

Humans1

Trial sponsors

Dana-Farber Cancer Institute
5 trialsPhase 2200 people
University of Rochester
2 trialsPhase 250 people
PETHEMA Foundation
1 trialPhase 290 people
International Myeloma Foundation
1 trialPhase 287 people
Landspitali University Hospital
1 trialPhase 280 people
Irene Ghobrial, MD
1 trialPhase 252 people
National Cancer Institute
1 trialPhase 223 people
Mayo Clinic
1 trialPhase 217 people

Latest

Leukemia1 Apr

Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression

Study in peopleMechanisms

American Journal of Hematology15 May

Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

Study in peopleBiomarkers

Blood Advances19 Jan

Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma

Cross-sectional study in peopleMechanisms